Bruno González-Zorn
Professor at the Complutense University of Madrid (UCM), Director of the UCM’s Antibiotic Resistance Unit, Chair of One Health at the ‘Una Europa’ alliance, and adviser to the WHO
My view is that the decline in antibiotic use is good news, but the data on resistance are worrying. Between 2024 and 2025, consumption fell by 5.8 per cent in Spain and by 6.9 per cent in the European Union. Even so, Spain continues to consume 21 per cent more than the EU as a whole and is still a long way from its 2030 target. In Spain, specific measures have helped, such as training prescribing professionals, adapting packaging to the duration of treatment, and deferred prescribing where indicated.
In that same year, the incidence of the three bloodstream infections with 2030 targets increased in both Spain and the EU. In Spain, I am particularly concerned about E. coli resistant to third-generation cephalosporins. Its incidence has risen by 76 per cent since 2019 and is almost double the Spanish target. The resurgence of methicillin-resistant Staphylococcus aureus is also striking. Last year we were close to meeting the target, and now we have once again exceeded the 2019 level. In the EU, it has also risen, although it remains within its target. As for carbapenem-resistant Klebsiella pneumoniae, Spain accounts for around a third of the European incidence, but since 2019 it has increased by more than 65 per cent in both cases.
These figures show that reducing antibiotic use, on its own, is not enough to control resistance. Using them properly remains essential, and in Spain we need to better understand where and how these bacteria are transmitted in order to stop that transmission. This requires a ‘One Health’ approach, integrating human, animal and environmental health. We must emphasise the prevention of infections in both people and animals, with specific measures such as handwashing, hygiene and the control of transmission in hospitals, care homes and livestock farms.
Lifelong vaccination is one of the key strategies, and there is scope to prevent disease in adults. The pneumococcal vaccine helps prevent bacterial infections. Vaccines against influenza, COVID-19 and respiratory syncytial virus, in the groups for which they are recommended, help prevent respiratory illness and its complications. By preventing infections and complications, we also reduce the instances in which an antibiotic may ultimately be required.
That is why we have launched a global integrated surveillance programme at the WHO that enables us to link data on antibiotic resistance and use across different sectors. And to ensure that these measures are implemented in practice, we also need to work with the social sciences. Their contribution is essential to understanding what makes it easier or more difficult for healthcare professionals and the general public to incorporate these measures into their daily lives.